cbdMD, Inc. (NYSEAMERICAN:YCBD) CFO Mark S. Elliott acquired 15,000 shares of the stock in a transaction dated Tuesday, January 14th. The stock was acquired at an average cost of $1.09 per share, with a total value of $16,350.00.
Shares of NYSEAMERICAN:YCBD traded up $0.05 during trading on Thursday, hitting $1.14. The company’s stock had a trading volume of 11,400 shares, compared to its average volume of 1,448,219. cbdMD, Inc. has a fifty-two week low of $0.99 and a fifty-two week high of $7.24.
A hedge fund recently raised its stake in cbdMD stock. State Street Corp boosted its position in cbdMD, Inc. (NYSEAMERICAN:YCBD) by 17.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 150,518 shares of the company’s stock after acquiring an additional 22,318 shares during the quarter. State Street Corp owned 0.54% of cbdMD worth $596,000 at the end of the most recent quarter.
YCBD has been the subject of a number of research reports. Benchmark dropped their price objective on shares of cbdMD from $9.00 to $7.00 and set a “speculative buy” rating for the company in a report on Thursday, December 19th. Cantor Fitzgerald began coverage on shares of cbdMD in a report on Thursday, November 7th. They set a “neutral” rating on the stock.
cbdMD Company Profile
cbdMD, Inc produces and distributes various cannibidiol (CBD) products in the United States. It operates through three segments: Products, Licensing, and Entertainment. The Products segment produces and markets CBD tinctures, capsules, gummies, bath bombs, vape oils, topical creams, and animal treats and oils under the cdbMD brand.
Read More: What are gap-down stocks?
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.